McAreavey D, Ramsay L E, Latham L, Lorimer A R, McLaren D, Reid J L, Robertson J I, Robertson M P, Weir R J
J Hypertens Suppl. 1983 Dec;1(2):116-9.
Hydralazine, labetalol, methyldopa, minoxidil, prazosin and placebo were compared when added to atenolol 100 mg and bendrofluazide 5 mg daily in hypertensive patients inadequately controlled by the beta-blocker/diuretic combination. Atenolol was withdrawn in those allocated to labetalol and minoxidil was given only to men. The order of acceptability was: placebo, hydralazine, prazosin, methyldopa, minoxidil, labetalol. All the active agents were more effective than placebo. Minoxidil was more effective than the other active drugs, which had similar potency to one another. Hydralazine was the most generally suitable third drug, with prazosin a close second. Minoxidil was effective in the milder hypertensives, but in the present regimen caused fluid retention in those with more severe hypertension. Labetalol probably should be introduced at lower dose (150 mg daily) even as replacement for full doses of a previously administered beta-blocker.
对于使用β受体阻滞剂/利尿剂联合治疗血压控制不佳的高血压患者,将肼屈嗪、拉贝洛尔、甲基多巴、米诺地尔、哌唑嗪与安慰剂,在每日服用100mg阿替洛尔和5mg苄氟噻嗪的基础上加用进行比较。分配到拉贝洛尔组的患者停用阿替洛尔,仅对男性给予米诺地尔。可接受性顺序为:安慰剂、肼屈嗪、哌唑嗪、甲基多巴、米诺地尔、拉贝洛尔。所有活性药物均比安慰剂更有效。米诺地尔比其他活性药物更有效,其他活性药物彼此效力相似。肼屈嗪是最普遍适用的第三种药物,哌唑嗪紧随其后。米诺地尔对轻度高血压患者有效,但在当前治疗方案中,会导致重度高血压患者出现体液潴留。拉贝洛尔可能应以较低剂量(每日150mg)开始使用,即使是作为先前服用的全剂量β受体阻滞剂的替代药物。